

CURRICULUM VITAE 	CURRICULUM FORMATIVO PROFESSIONALE REDATTO SU CARTA SEMPLICE ED IN FORMA DI DICHIARAZIONE SOSTITUTIVA AI SENSI DEGLI ARTT. 46 E 47 DEL DPR 28 DICEMBRE 2000, N. 445
INFORMAZIONI PERSONALI	
<i>Nome</i>	Massimo
<i>Cognome</i>	Martino
<i>E-mail</i>	massimo.martino@ospedalcrc.it
<i>PEC mail</i>	massimo.martino.lwjb@rc.omceo.it
<i>Cittadinanza</i>	Italiana
<i>Data di nascita</i>	=====
<i>Luogo di nascita</i>	Reggio Calabria (Italia)
<i>Sesso</i>	Maschile
<i>C.F.</i>	=====
<i>Professione</i>	Medico-Chirurgo
Istruzione e formazione	
<i>Specializzazioni</i>	Specializzazione in Ematologia Generale, Università di Messina in data 01-10-2000, votazione 50 e lode/50 discutendo la tesi “Autotrapianto di cellule Staminali Periferiche (PBSC) nel Mieloma Multiplo. Fattibilità in regime ambulatoriale” Specializzazione in Geriatria, Università di Messina in data 04-11-1994, votazione 48/50
<i>Ordine Professionale</i>	Iscritto all'albo dei Medici-Chirurghi di Reggio Calabria al n.6276/RC dalla data del 26-06-1990
<i>Abilitazione Professionale</i>	Abilitazione Medica , Università di Messina, Anno 1990
<i>Laurea</i>	Medicina e Chirurgia , presso l'Università di Messina in data 06-04-1990, con votazione 110 e lode/100.
<i>Altri titoli Accademici</i>	Qualifica scientifica nazionale di Professore Associato in Ematologia
Incarico Professionale Attuale	
	Da marzo 2024, Direttore “ad interim” Unità Complessa Ematologia, Dipartimento Onco-Ematologico e Radioterapico, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli” di Reggio Calabria

	Dall'Agosto 2017, Direttore Unità Complessa Centro Trapianti Midollo Osseo (denominazione Aziendale "CTMO"), Dipartimento Onco-Ematologico e Radioterapico, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" di Reggio Calabria Direttore Programma Trapianti CIC 587, Centro Nazionale Trapianti Coordinatore Aziendale del Team Multidisciplinare, finalizzato alla gestione della terapia con linfociti geneticamente modificati (CAR-T)
<i>Caratteristiche reparti Ematologia e CTMO</i>	
	Il CTMO è struttura certificata secondo: • Joint Accreditation Committee-ISCT & EBMT (JACIE) • Istituto Superiore di Sanità (ISS) • Centro Nazionale Sangue (CNS) • Centro Nazionale Trapianti (CNT) • Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali e Terapia Cellulare (GITMO) per svolgere attività di: Trapianto Autologo, Trapianto Allogeneico da donatore familiare identico, da donatore non familiare, da donatore familiare aploidentico, aggiornamento follow-up dei trapianti allogeneici. • ISO 9001 Bureau Veritas Certification • Struttura Accreditata da AIFA e Regione Calabria per la somministrazione di terapia cellulare con linfociti geneticamente modificati (CAR-T) (risultato ottenuto sotto la Direzione del dr. Massimo Martino) • Accreditamento con le aziende farmaceutiche NOVARTIS, BMS, e KITE/GILEAD, Johnson & Johnson per la somministrazione commerciale di linfociti T geneticamente modificati (CAR-T)
<i>Indirizzo Amministrazione</i>	
	Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli" Reggio Calabria, Via Provinciale Spirito Santo, 24 89100 - Reggio Calabria (RC)
Altri Incarichi Professionali espletati o in corso	
	Da Maggio 2023: Presidente eletto della società scientifica GITMO (Gruppo Italiano Trapianti Midollo Osseo e Terapie Cellulari) Dal Giugno 2021: Membro eletto Working Party Immunoterapie – Gruppo GIMEMA Dal Giugno 2021: Associate Editor for Hematologic Malignancies Frontiers in Oncology Marzo 2021: Nomina Aziendale in qualità di coordinatore del Team Multidisciplinare

	Terapia CAR T (delibera n. 188 del 30-03-2021) Maggio 2019-Maggio 2023 componente eletto del Direttivo Nazionale della società scientifica GITMO (Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare), dove ha svolto il ruolo di Vicepresidente Anno 2019: nomina in qualità di componente della Commissione Co.Bu.S (Comitato Buon Uso del Sangue), del GOM di Reggio Calabria (delibera n. 120 del 28-02-2019) Novembre 2018 – Maggio 2023 componente eletto del Direttivo Nazionale GIIMA (Gruppo Italiano Interdisciplinare Manipolazione e Aferesi per Terapie Cellulari) Maggio 2018- Maggio 2019: delegato eletto regionale per la società scientifica GITMO (Gruppo Italiano per il Trapianto di Midollo Osseo, cellule staminali emopoietiche e terapia cellulare) Nomina da parte della Regione Calabria nel gruppo di lavoro per la stesura di linee guida di appropriatezza prescrittiva per farmaci Ematologici (DCA N. 88/2017) (Registro dei decreti dei Dirigenti della Regione Calabria” N°. 4817 del 17/05/2018) Anno 2017: componente Commissione per il piano della performance 2018-2021 del Grande Ospedale Metropolitano BMM di Reggio Calabria Anno 2017: componente Commissione per la valutazione relativa all’appropriatezza e la razionalizzazione dei farmaci oncologici, presso il Grande Ospedale Metropolitano BMM di Reggio Calabria Anno 2015: componente del comitato scientifico Grande Ospedale Metropolitano BMM di Reggio Calabria, attenenti alla validazione del piano formativo a livello scientifico 2007-2017: nomina presso il Centro Nazionale Trapianti, Centro Nazionale Sangue, Centro Regionale per i Trapianti Calabria, Centro Regionale di Coordinamento per le Attività Trasfusionali, in qualità di responsabile delle attività di prelievo delle Cellule Staminali Emopoietiche (Prot. SIT 810 del 03-10-2007 e Prot. CTMO 1713 del 03-10-2007) Dalla data del 08-07-2005 al 10-08-2017: responsabile Gruppo Italiano Trapianto Midollo Osseo (GITMO), Unità Raccolta CSE (Cellule Staminali Emopoietiche) del Centro Trapianti Midollo Osseo dell’Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria Dalla data del 11-08-2017: Direttore Programma Trapianto in ambito GITMO del Centro Trapianti Midollo Osseo dell’Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria (CIC 587)
Competenze Professionali	• Diagnosi, terapia e follow-up in pazienti affetti da: Mieloma Multiplo; Malattia di Hodgkin; Linfoma non Hodgkin; Leucemia Acuta mieloide;

	Leucemia Acuta linfoblastica; Leucemia Mieloide Cronica; Leucemia Linfatica Cronica; Mielodisplasia; Mielofibrosi; Aplasia midollare; Anemia; Piastrinopenie • Chemioterapia convenzionale ed ad alte dosi, condizionamenti nelle neoplasie ematologiche, nelle patologie autoimmuni, nelle anemie aplastiche • Chemioterapia non mielo-ablativa e condizionamenti nelle neoplasie ematologiche e nelle anemie plastiche • Immunoterapia, in particolare con linfociti geneticamente modificati (CAR-T) • Trapianto di cellule staminali autologhe; Trapianto di cellule staminali allogeniche da donatore familiare, da donatore MUD e da donatore aploidentico • Complicanze infettive e tossiche in corso di chemioterapia e trapianto • Complicanze da GVH post-trapianto • Followp del paziente trapiantato • Raccolta di cellule staminali autologhe e allogeniche, sia dal sangue periferico che midollo osseo • Tipizzazioni HLA • Problematiche coagulative per identificazione eventi emorragici e trombotici • Competenze documentate nella didattica in particolare con riferimento ai percorsi formativi delle tecniche diagnostico/terapeutiche di interesse Ematologico. • Esperienza consolidata nella didattica per tematiche inerenti all'Ematologia ed il Trapianto di Cellule Staminali
Finanziamenti Scientifici	Principal Investigator di numero studi clinici in Ematologia • Vincitore Bando PNRR 2022: P.I. del progetto di ricerca PNRR-MCNT1-2023-12377456 dal titolo "Decoding the inflammasome influence on treatment response in acute myeloid leukemia". Capofila del progetto Ospedale San Raffaele, Milano • Vincitore Bando PNRR 2023: Coordinatore del Centro di Reggio Calabria del progetto di ricerca PNRR-MCNT2-2023-12377304 dal titolo "Impact of postbiotic administration on the immune- reconstitution and clinical outcome of bone marrow transplantation: a double-blind randomized interventional study". Capofila del progetto Ospedale Pediatrico Bambino Gesù, Roma • Vincitore Bando PNRR 2022: P.I. del progetto di ricerca PNRR-MAD-2022-12376816

	dal titolo “Complement related gene abnormalities in transplant associated thrombotic microangiopathy (TA-TMA). Capofila del progetto Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano • Responsabile Scientifico del progetto “Ospedalizzazione domiciliare HOME Care”, convenuto con delibera n. 178 del 13-04-2010, tra l’Azienda Ospedaliera BMM e l’AIL di Reggio Calabria per la gestione della fase di aplasia post-trapianto in regime domiciliare. Tale progetto, è stato finanziato dall’AIL nazionale
Società scientifiche di cui è socio	
	• E.B.M.T. (Gruppo Europeo Trapianto di Midollo Osseo) • E.H.A. (Società Europea di Ematologia) • GITMO (Gruppo Italiano Trapianti Midollo Osseo) • S.I.E. (Società Italiana di Ematologia) • S.I.E.S. (Società Italiana di Ematologia Sperimentale) • S.I.d.E.M. (Società Italiana di Emaferesi e Manipolazione Cellulare)
Reviewer per le seguenti riviste scientifiche	
	• Acta Oncologica • American Journal of Hematology • Biology of Blood and Marrow Transplantation • Bone Marrow Transplantation • Cancer • Hematologica • Transfusion and Apheresis Science • Turkish Journal of Hematology • Leukemia & Lymphoma • Journal of Clinical Apheresis • Vox Sanguinis • The Lancet
Esperienze Professionali	
	• Attuale Direttore “ad interim” dell’Unità Complessa di Ematologia, del Dipartimento Onco-Ematologico e Radioterapico, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli” di Reggio Calabria con decorrenza marzo 2024 • Attuale Direttore dell’Unità Complessa Centro Trapianti Midollo

	Osseo (CTMO), del Dipartimento Onco-Ematologico e Radioterapico, Grande Ospedale Metropolitano “Bianchi-Melacrino-Morelli” di Reggio Calabria con decorrenza 11-08-2017 (delibera n. 460 del 04-08-2017) • Alta Specialità “Day-Hospital, Ambulatorio e Collezioni Cellule Staminali per uso Terapeutico”, afferente all’U.O.C. CTMO (Dipartimento Onco-Ematologico e Radioterapico, Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria) con decorrenza 01-05-2015 (delibera n.16 del 20-04-2015) e per la durata di anni tre • Responsabile Struttura semplice “Cellule staminali” afferente all’U.O.C. CTMO (Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria) (deliberazione n. 691 del 09-10-2007) con decorrenza dal 01-01-2008. Con delibera n.425 del 01-04-2014, si è preso atto del verbale di valutazione, per il predetto incarico di cui alla delibera n. 691 del 09-10-2007, ai sensi dell’art. 33 del CCNL 98/01 e ss.mm. ii. effettuata dal collegio con esito positivo. • Incarico di funzione “Ambulatorio e patologie secondarie del trapiantato” dell’U.O.C Ematologia con trapianto + terapia intensiva CTMO (Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria) dal 01-01-1996 fino al 31-12-2007 (deliberazione n.269 del 16-02-1999). • In esecuzione al CCNL 1994/1997 dal 06-12-1996 al 10-08-2017, Dirigente Medico con rapporto di lavoro a tempo indeterminato presso U.O.C. CTMO (Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria). • Con la costituzione delle Aziende Sanitarie Locali e delle Aziende Ospedaliere, ai sensi della L.R. n.26/94 è stato assegnato all’Azienda Ospedaliera “Bianchi-Melacrino-Morelli” di Reggio Calabria e ha continuato a prestare servizio presso l’U.O.C. CTMO, quale Assistente Medico di ruolo con rapporto di lavoro a tempo pieno dal 30-01-1995 al 05-12-1996. • Servizio presso U.S.L. n. 31 e, successivamente, a seguito dell’accorpamento, presso l’U.S.L. n. 11 della Regione Calabria, dal 07-01-1992 al 29-01-1995 quale Assistente Medico di ruolo con rapporto di lavoro a tempo pieno, presso l’U.O. l’Ematologia con Trapianti Midollo Osseo e Terapia Intensiva (CTMO) (Ospedale
--	--

	Bianchi-Melacrino-Morelli di Reggio Calabria) Assistente volontario presso il Dipartimento di Medicina Interna dell'Ospedale "Bianchi-Melacrino-Morelli" di Reggio Calabria dal 1990 al 1992
Principali Lavori scientifici	1: Alati C, Pitea M, Molica M, Rossi M, Alvaro ME, Porto G, Bilardi E, Utano G, Policastro G, Micò MC, Marafioti V, Martino M. Is There a Future for CAR-T Therapy in Acute Myeloid Leukemia? <i>Cancers (Basel)</i>. 2025 Dec 29;18(1):107. doi: 10.3390/cancers18010107. PMID: 41514619; PMCID: PMC12784666. 2: Polverelli N, Pitino A, Defrancesco I, Saporiti G, Onida F, Federico V, Carella AM, Salvatore D, Tripepi G, Zerbi C, Micò MC, Policastro G, Porto G, Canale FA, Alati C, Loteta B, Picardi A, D'Arrigo G, Gori M, Martino M. Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis. <i>Bone Marrow Transplant</i>. 2025 Dec 26. doi: 10.1038/s41409-025-02791-z. Epub ahead of print. PMID: 41454024. 3: Porto G, Pitino A, Gori M, Pitea M, Alvaro ME, Tripepi GL, Policastro G, Martino F, Minniti RD, Germano J, Loteta B, Utano G, Bilardi E, Cogliandro F, Alati C, Marafioti V, D'Arrigo G, Martino M. Efficacy of Polyvinylpyrrolidone-Zinc Gluconate and Taurine Gel in the Prophylaxis of Oral Mucositis in Adults Undergoing High-Dose Chemotherapy and Allogeneic Stem Cell Transplantation. <i>Diseases</i>. 2025 Dec 18;13(12):408. doi: 10.3390/diseases13120408. PMID: 41439949; PMCID: PMC12732068. 4: Molica M, Simio C, De Fazio L, Alati C, Martino M, Rossi M. Harnessing Venetoclax in NPM1-Mutated AML: A Path to Sustained Remission and Beyond. <i>Cancers (Basel)</i>. 2025 Nov 21;17(23):3733. doi: 10.3390/cancers17233733. PMID: 41374935; PMCID: PMC12691402. 5: Vetro C, Garibaldi B, Grimaldi F, Chiusolo P, Filì C, Riva C, Cardinali V, Franciosa M, Pilo F, Palmieri R, Esposito L, Menotti D, Perrone S, Mulè A, Alati C, Vigna E, Dargenio M, De Luca G, Sperotto A, Tanasi I, Papayannidis C, Molica M, Minetto P, Battipaglia G, Memoli M, Salutari P, Brunetti L, Todisco E, Lotesoriere I, Isidori A, Palumbo GA, Annunziata M, Gottardi M, Gentile M, Martelli MP, Capelli D, Martino M, Rossi M, Ferrara F, Venditti A, Romani C, Galimberti S, Candoni A, Fianchi L, Pagano L, Marconi G, Lemoli RM, Di Raimondo F, Billio A, Palumbo FE, Pane F, Duminuco A, Guolo F. Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia. <i>Blood Cancer J</i>. 2025 Dec 4;15(1):213. doi: 10.1038/s41408-025-01431-5. Erratum for: <i>Blood Cancer J</i>. 2025 Oct 26;15(1):181. doi: 10.1038/s41408-025-01394-7. PMID: 41345216; PMCID: PMC12678793. 6: Polverelli N, Zerbi C, Benevento MG, Algeri M, Algarotti A, Angelucci E, Balduzzi AC, Basiricò M, Bassi S, Battipaglia G, Benedetti E, Biffi A, Bonifazi F, Borghero C, Bramanti S, Brunello L, Bresciani P, Busca A, Cairoli R, Carluccio P, Carobolante F, Carella AM, Cavattoni IM, Cerretti R, Chiappella A, Chiusolo P, Cimminiello M, Corradini P, Crescimanno A, Cuoghi A, Di Renzo N, Fagioli F, Fanin R, Faraci M, Federico V, Geromin A, Giaccone L, Giacomazzi A, Grassi A, Grillo G, Imovilli A, Ingrosso C, Iori AP, La Nasa G, Leotta S, Lupo Stanghellini MT, Mancini G, Mariotti J, Mele A, Menconi M, Merli F, Mordini N, Musso M, Nozzoli C, Pane F, Parma M, Pastano R, Pastore D, Patriarca F, Picardi A, Piemontese S, Pierini A, Piras E, Porta F, Porto G, Prete A, Prezioso L, Proia A, Raiola A, Ricci R, Roberto M, Rosignoli C, Russo D, Salvatore D,

Santarone S, Saporiti G, Saraceni F, Selleri C, Serio B, Skert C, Sica S, Spina A, Tambaro FP, Tecchio C, Terruzzi E, Tumino M, Vallisa D, Zallio F, Zecca M, Taurino A, Bianchessi A, Defrancesco I, Losi G, Degrandi E, Malagola M, Castagna L, Martino M. Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study. *Am J Hematol*. 2026 Feb;101(2):350-355. doi: 10.1002/ajh.70145. Epub 2025 Nov 25. PMID: 41292154.

7: Alati C, Pitea M, Porto G, Bilardi E, Greve MB, Vincelli ID, Rizzuto A, Policastro G, Alvaro ME, Utano G, Gerace D, Allegra A, Piro E, Rossi M, Martino M. SLAMF7: A Potential Target for CAR T-Cell Therapy in Multiple Myeloma. *Cancers (Basel)*. 2025 Oct 29;17(21):3471. doi: 10.3390/cancers17213471. PMID: 41228264; PMCID: PMC12609652.

8: Vetro C, Garibaldi B, Grimaldi F, Chiusolo P, Filì C, Riva C, Cardinali V, Franciosa M, Pilo F, Palmieri R, Esposito L, Menotti D, Perrone S, Mulè A, Alati C, Vigna E, Dargenio M, De Luca G, Sperotto A, Tanasi I, Papayannidis C, Molica M, Minetto P, Battipaglia G, Memoli M, Salutati P, Brunetti L, Todisco E, Lotesoriere I, Isidori A, Palumbo GA, Annunziata M, Gottardi M, Gentile M, Martelli MP, Capelli D, Martino M, Rossi M, Ferrara F, Venditti A, Romani C, Galimberti S, Candoni A, Fianchi L, Pagano L, Marconi G, Lemoli RM, Di Raimondo F, Billio A, Palumbo FE, Pane F, Duminuco A, Guolo F. Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia. *Blood Cancer J*. 2025 Oct 26;15(1):181. doi: 10.1038/s41408-025-01394-7. Erratum in: *Blood Cancer J*. 2025 Dec 4;15(1):213. doi: 10.1038/s41408-025-01431-5. PMID: 41139766; PMCID: PMC12554896.

9: Molica M, Simio C, De Fazio L, Alati C, Rossi M, Martino M. The Evolving Role of Hematopoietic Stem Cell Transplantation in Philadelphia-like Acute Lymphoblastic Leukemia: From High-Risk Standard to Precision Strategies. *Cancers (Basel)*. 2025 Oct 5;17(19):3237. doi: 10.3390/cancers17193237. PMID: 41097763; PMCID: PMC12523408.

10: Alati C, Pitea M, Molica M, Scalise L, Porto G, Bilardi E, Lazzaro G, Micò MC, Pugliese M, Canale FA, Loteta B, Naso V, Policastro G, Utano G, Rizzuto A, Marafioti V, Rossi M, Martino M. CAR-T Cell Therapies in B-Cell Acute Lymphoblastic Leukemia: Emerging Data and Open Issues. *Cancers (Basel)*. 2025 Sep 16;17(18):3027. doi: 10.3390/cancers17183027. PMID: 41008869; PMCID: PMC12468742.

11: Caracciolo D, Canale FA, Naso V, Alati C, Marafioti V, Porto G, Tedesco L, Pensabene G, Martino EA, Allegra A, Gerace DG, Cimminiello M, Gentile M, Tagliaferri P, Tassone P, Martino M. CD19 CAR-T Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study from the Calabria Referral Center in Southern Italy. *Cancers (Basel)*. 2025 Aug 27;17(17):2796. doi: 10.3390/cancers17172796. PMID: 40940893; PMCID: PMC12427354.

12: Luminari S, Chiappella A, Rocco AD, Arcaini L, Freilone R, Ladetto M, Martino M, Musto P, Rigacci L, Visco C, Corradini P, Zinzani PL. Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi consensus. *Cytotherapy*. 2025 Nov;27(11):1316-1325. doi: 10.1016/j.jcyt.2025.07.007. Epub 2025 Jul 25. PMID: 40928447.

13: Malagola M, Castagna L, Matranga D, Radici V, Farina M, Galli M, Accorsi

Buttini E, Rubini V, Alati C, Bassi S, Biffi A, Borghero C, Busca A, Nozzoli C, Carella Angelo M, Cavattoni I, Cerretti R, Chiusolo P, Cimminiello M, Cuoghi A, De Gobbi M, Vincenzo F, Galieni P, Iori Anna P, Olivieri A, Parma M, Patriarca F, Pavone V, Picardi A, Piras E, Polverelli N, Prezioso L, Rambaldi B, Scalisi E, Selleri C, Skert C, Spina A, Tecchio C, Oldani E, Eliana D, Domenico R, Martino M. Outcome of Patients With Acute Myeloid Leukemias or Myelodysplastic Syndromes After Relapsing From Allogeneic Stem Cell Transplantation: The GITMO AML/MDS-Relapse Registry Study. *Am J Hematol.* 2025 Oct;100(10):1902-1905. doi: 10.1002/ajh.70030. Epub 2025 Aug 6. Erratum in: *Am J Hematol.* 2026 Feb;101(2):402. doi: 10.1002/ajh.70151. PMID: 40767512.

14: Battista ML, Facchin G, De Martino M, Chiusolo P, Russo D, Malagola M, Saraceni F, Mancini G, Rambaldi A, Cavattoni IM, Lico A, Nozzoli C, Cuoghi A, Ladetto M, Federico V, Micò MC, Lupo-Stanghellini MT, Oldani E, Degrandi E, Gallina AM, Parma M, Biffi A, Fagioli F, Skert C, Geromin A, Savignano C, Isola M, Fanin R, Ciceri F, Martino M, Patriarca F. Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy. *Bone Marrow Transplant.* 2025 Oct;60(10):1406-1409. doi: 10.1038/s41409-025-02674-3. Epub 2025 Jul 26. PMID: 40715542.

15: Girmenia C, Lazzarotto T, Martino M, Bonifazi F, Baldanti F, Clerici P, Citterio F, De Carlis L, Barosi G, Grossi PA. Management of Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell and in Solid Organ Transplantation: Updated Recommendations by the GITMO, SITO, SIMIT, and AMCLI Italian Societies. *Clin Transplant.* 2025 Aug;39(8):e70255. doi: 10.1111/ctr.70255. PMID: 40709451.

16: Vicinanza R, Frizza A, Pollard JA, Mazza V, De Martino MU, Imbimbo G, Pignatelli P, Ettorre E, Del Ben M, Molfino A. Aging and IGF-I: relationships with vitamin D and body composition. A mediation analysis. *Front Nutr.* 2025 Jun 24;12:1585696. doi: 10.3389/fnut.2025.1585696. PMID: 40630171; PMCID: PMC12234294.

17: Cioce M, Vetrugno G, Iula A, Cornacchione P, Botti S, Zoboli V, Cerretti R, Soave S, Guidi B, Gobbi G, Finotto S, Bettini D, Mordini N, Dutto E, Mele A, Sperti G, Congedo R, De Cecco V, Picardi A, Buonanno D, Carella AM, Steduto M, Lupo-Stanghellini MT, Carmagnola A, Faraci M, Deiana M, Visintini C, Cimminiello M, Lerosé E, Sica S, Lamberti F, Grassi VM, Di Donato M, Nuzzo C, Martino M. Perception of 'patient safety culture' among healthcare professionals in the field of haematopoietic stem cell transplantation and CAR-T therapy: a multicentre cross-sectional observational study by Italian Transplant Group for Bone Marrow Transplantation, Haematopoietic Stem Cells and Cell Therapy (GITMO). *BMJ Open Qual.* 2025 Jul 7;14(3):e003318. doi: 10.1136/bmjopen-2025-003318. PMID: 40623859; PMCID: PMC12258342.

18: Botti S, Lupo R, Pollichieni S, Sacchi N, Serra N, Cioce M, Pupella S, Ciceri F, Vassanelli A, Lombardini L, Martino M, Rubbi I, Ianne C, Lezzi A, Rea T, Guillari A, Capuano A, Cascio D, Vitale E, De Nunzio G, Conte L. Exploring Italians' knowledge of, and perceptions and feelings about stem cell donation: a GITMO-IBMMDR nationwide survey. *Blood Transfus.* 2025 Nov-Dec;23(6):477-491. doi: 10.2450/BloodTransfus.986. PMID: 40522316; PMCID: PMC12591928.

19: Defrancesco I, Ferretti VV, Chiusolo P, Russo D, Nozzoli C, Olivieri A, Gambella M, Cavattoni IM, Bramanti S, Santarone S, Fanin R, Cairoli R,

Piemontese S, Parma M, Onida F, Busca A, Castagna L, Cuoghi A, Pastore D, Mordini N, Benedetti F, Skert C, Borghero C, Iori AP, Fagioli F, Pavone V, Selleri C, Cesaro S, Musso M, Ladetto M, Vallisa D, Carluccio P, Picardi A, Tozzi M, Biffi A, Milone G, Faraci M, Prete A, Prezioso L, Risitano AM, Tambaro FP, Tintori V, Galieni P, Pane F, Zerbi C, Bianchessi A, Losi G, Romano F, Taurino A, Oldani E, Polverelli N, Bonifazi F, Martino M. Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry-Based Study on Behalf of the "Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare" (GITMO). *Am J Hematol.* 2025 Aug;100(8):1354-1364. doi: 10.1002/ajh.27731. Epub 2025 Jun 2. PMID: 40456127; PMCID: PMC12232522.

20: Magni M, Jonnalagadda S, Bonifazi F, Bonafe M, Ljevar S, Zanirato G, De Matteis S, Stella F, Barone A, Bertolini G, Bermema A, Chiappella A, Tisi MC, Cutini I, Novo M, Grillo G, Farina M, Martino M, Krampera M, Massaia M, Arcaini L, Bramanti S, Zinzani PL, Doderio A, Corradini P, Carniti C. CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study. *Haematologica.* 2025 Nov 1;110(11):2661-2672. doi: 10.3324/haematol.2025.287528. Epub 2025 May 29. PMID: 40438977; PMCID: PMC12580699.

21: Girmenia C, Chiusolo P, Marsili G, Piciocchi A, Micò MC, Greco R, Porto G, Galaverna F, Bonifazi F, Cutini I, Malagola M, Bramanti S, Busca A, Carella AM, Carotti A, Iori AP, Onida F, Bono R, Terruzzi E, Vacca A, Rinaldi A, Cavattoni IM, Picardi A, Faraci M, Lazzarotto T, Baldanti F, Clerici P, Castagna L, Martino M, Ciceri F. The Changing Impact of Human Cytomegalovirus Serology and Infection on Patient Outcome After Allogeneic Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey in the Era of Letemovir Prophylaxis. *Open Forum Infect Dis.* 2025 Apr 18;12(5):ofaf233. doi: 10.1093/ofid/ofaf233. PMID: 40322267; PMCID: PMC12048776.

22: Polverelli N, Hernández-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sánchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke V, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison C, Hobbs G, Jain T, Khoury JD, Kiladjan JJ, Kröger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. *Blood.* 2025 May 29;145(22):2561-2573. doi: 10.1182/blood.2024028000. PMID: 40106773.

23: Naso V, Canale F, Policastro G, Porto G, Pellicano M, Martino M. Terapia cellulare CAR-T in un paziente affetto da linfoma mantellare recidivato/refrattario [CAR-T cell therapy in a patient with relapsed/refractory mantle cell lymphoma]. *Recenti Prog Med.* 2025 Mar;116(3):e50-e57. Italian. doi: 10.1701/4460.44570. PMID: 40084460.

24: Farina M, Bernardi S, Malagola M, Re A, Galli E, Riva M, Cutini I, Leoni A, Martino M, Ferrari S, Battipaglia G, Novo M, Musso M, Grillo G, Santarone S, Krampera M, Aroldi A, Polverelli N, Arcaini L, Xhahysa B, Avenoso D, Tisi MC, Chiusolo P, Russo D. Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study. *Bone Marrow Transplant.* 2025 May;60(5):702-704. doi: 10.1038/s41409-025-02529-x. Epub 2025 Feb 15. PMID: 39955412; PMCID: PMC12061764.

- 25: La Rocca U, Ricci R, Piciocchi A, Barberi W, Oldani E, Dominietto A, Cerretti R, Picardi A, Bonifazi F, Saccardi R, Faraci M, Grillo G, Farina L, Bruno B, Grassi A, Proia A, Tagliaferri E, De Simone G, Malagola M, Cerno M, Cesaro S, Bernasconi P, Prezioso L, Carluccio P, Mordini N, Pelosini M, Olivieri A, Chiusolo P, Santarone S, Cimminiello M, Crocchiolo R, Papola F, Rombolà G, Sacchi N, Miotti V, Mele L, Mazzi B, Ciceri F, Martino M, Iori AP. Donor-specific anti-HLA antibodies (DSAs) in patients undergoing allogeneic hematopoietic stem cell transplantation from mismatched donors on behalf of GITMO and AIBT. *Blood Transfus.* 2025 Mar;23(2):176-185. doi: 10.2450/BloodTransfus.790. Epub 2025 Jan 28. PMID: 39949023; PMCID: PMC11925252.
- 26: Conte L, De Nunzio G, Lupo R, Cascio D, Cioce M, Vitale E, Ianne C, Rubbi I, Martino M, Lombardini L, Vassanelli A, Pupella S, Pollichieni S, Sacchi N, Ciceri F, Botti S. Correction: Raising awareness may increase the likelihood of hematopoietic stem cell donation: a nationwide survey using artificial intelligence. *Int J Hematol.* 2025 Apr;121(4):563. doi: 10.1007/s12185-025-03932-2. Erratum for: *Int J Hematol.* 2025 Apr;121(4):511-525. doi: 10.1007/s12185-024-03894-x. PMID: 39946022.
- 27: Raiola AM, Bruno B, Risitano AM, Mosna F, Cavattoni IM, Onida F, Saporiti G, Patriarca F, Battista ML, Pavone V, Mele A, Chiusolo P, Sica S, Loteta B, di Grazia C, Carella AM, Salvatore D, Morello E, Leoni A, Giaccone L, Bernasconi P, Terruzzi E, Mordini N, Borghero C, Zallio F, Luppi M, Grassi A, Olivieri A, Piras E, Sacchi N, Ciccone G, Castiglione A, Degrandi E, Angelucci E, Martino M, Bonifazi F. Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trial. *Blood Adv.* 2025 Apr 22;9(8):1966-1975. doi: 10.1182/bloodadvances.2024015173. PMID: 39928954; PMCID: PMC12018986.
- 28: Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Rocco AD, Tisi MC, Angelillo P, Cutini I, Martino M, Barone A, Bonifazi F, Santoro A, Sorà F, Novo M, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Brunello L, Cavallo F, Massaia M, Arcaini L, Farina L, Zinzani P, Miceli R, Corradini P. Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study. *Transplant Cell Ther.* 2025 Apr;31(4):240.e1-240.e9. doi: 10.1016/j.jtct.2025.01.888. Epub 2025 Jan 25. PMID: 39870308.
- 29: Malagola M, Castagna L, Farina M, Pellizzeri S, Degrandi E, Oldani E, Bassi S, Battipaglia G, Borghero C, Brunello L, Busca A, Ceretti R, Chiusolo P, Cimminiello M, Federico V, Frieri C, Galieni P, Galimberti S, Gilioli A, Imovilli A, Barbieri W, Nozzoli C, Picardi A, Piras E, Polverelli N, Prezioso L, Santarone S, Scalone R, Scortechini I, Serio B, Skert C, Spina A, Terruzzi E, Martino M. Assessment of frailty and comorbidities in cellular therapies patients in Italy: results of the GITMO Elderly-Survey (GITMO ELD-Survey). *Leuk Lymphoma.* 2025 Jun;66(6):1142-1145. doi: 10.1080/10428194.2025.2451723. Epub 2025 Jan 15. PMID: 39813626.
- 30: Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, Cutini I, Ljevar S, Barbui AM, Farina M, Martino M, Massaia M, Grillo G, Angelillo P, Botto B, Patriarca F, Krampera M, Arcaini L, Tisi MC, Zinzani P, Sorà F, Bramanti S, Pennisi M, Carniti C, Corradini P. Brexucabtagene autoleucel in-vivo

	expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study. <i>Br J Haematol.</i> 2025 Feb;206(2):644-651. doi: 10.1111/bjh.19961. Epub 2024 Dec 22. PMID: 39710966; PMCID: PMC11829141. 31: Conte L, De Nunzio G, Lupo R, Cascio D, Cioce M, Vitale E, Ianne C, Rubbi I, Martino M, Lombardini L, Vassanelli A, Pupella S, Pollichieni S, Sacchi N, Ciceri F, Botti S. Raising awareness may increase the likelihood of hematopoietic stem cell donation: a nationwide survey using artificial intelligence. <i>Int J Hematol.</i> 2025 Apr;121(4):511-525. doi: 10.1007/s12185-024-03894-x. Epub 2024 Dec 12. Erratum in: <i>Int J Hematol.</i> 2025 Apr;121(4):563. doi: 10.1007/s12185-025-03932-2. PMID: 39668285. 32: Martino M, Pitea M, Sgarlata A, Delfino IM, Cogliandro F, Scopelliti A, Marafioti V, Polimeni S, Porto G, Policastro G, Utano G, Pellicano M, Leanza G, Alati C. Treatment Strategies Used in Treating Myelofibrosis: State of the Art. <i>Hematol Rep.</i> 2024 Oct 30;16(4):698-713. doi: 10.3390/hematolrep16040067. PMID: 39584924; PMCID: PMC11587016. 33: Nozzoli C, Pucillo M, Giaccone L, Rambaldi A, Stanghellini MTL, Benedetti E, Russo D, Mordini N, Mangiacavalli S, Bernasconi P, Parma M, Carluccio P, Galieni P, Rivela P, Martino M, Chiusolo P, Isola M, De Martino M, Oldani E, Degrandi E, Boncompagni R, Antonioli E, Carnevale F, Tozzi M, Sella C, Fanin R, Patriarca F; Gruppo Italiano Trapianto Midollo Osseo (GITMO). Novel Drug Combinations and Donor Lymphocyte Infusions Allow Prolonged Disease Control in Multiple Myeloma Patients Relapsing after Allogeneic Transplantation. <i>Transplant Cell Ther.</i> 2025 Jan;31(1):26.e1-26.e13. doi: 10.1016/j.jtct.2024.10.015. Epub 2024 Nov 4. PMID: 39505212. 34: Porrazzo M, Moscato T, Sapienza G, Accardi F, Patti C, Cangialosi C, Costanza C, Bono R, Tringali S, Rotolo C, Gigliotta E, Rizzuto A, Ingrassia MG, Butera G, Di Noto L, Santoro A, Marfia A, Botta C, Siragusa S, Martino M, Castagna L. Impact of daratumumab/bortezomib/thalidomide and dexamethasone induction therapy on chemo-free stem cell mobilization in transplant-eligible newly diagnosed multiple myeloma: a multicenter real-world experience. <i>Haematologica.</i> 2025 Mar 1;110(3):791-794. doi: 10.3324/haematol.2024.286332. PMID: 39479867; PMCID: PMC11873712. 35: Morabito F, Martino EA, Nizzoli ME, Talami A, Pozzi S, Martino M, Neri A, Gentile M. Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma. <i>Eur J Haematol.</i> 2025 Jan;114(1):4-16. doi: 10.1111/ejh.14335. Epub 2024 Oct 27. PMID: 39462177; PMCID: PMC11613673. 36: Lambert N, Forte F, El Moussaoui M, Monseur J, Raus N, Polushin A, Michonneau D, Shultz C, Hogan WJ, Balaguer-Roselló A, Gil-Perotín S, Brijs J, Chauvet P, Gavrilaki M, Carre M, Dulamea AO, Chalandon Y, Salmenniemi U, Duminuco A, Ram R, García-Cadenas I, Porto G, Nguyen S, Smallbone P, González-Vicent M, Santoro JD, Willems E, Baron F, Servais S, Beguin Y, Maquet P; CNS-GvHD Study Group. CNS manifestations in acute and chronic graft-versus-host disease. <i>Brain.</i> 2025 Apr 3;148(4):1122-1133. doi: 10.1093/brain/awae340. PMID: 39442000; PMCID: PMC11967822. 37: Martino M, Gori M, Porto G, Policastro G, Pitea M, Sgarlata A, Delfino IM, Cogliandro F, Scopelliti A, Utano G, Pellicano M, Idato A, Vincelli ID, Marafioti V, Micò MC, Lazzaro G, Loteta B, Alati C, Leanza G, D'Arrigo G, Tripepi GL, Pitino A. First-Line Use of Daratumumab in Patients with Multiple
--	---

Myeloma Shows Delayed Neutrophil and Platelet Engraftment after Autologous Stem Cell Transplantation: Results from a Real-Life Single-Center Study. *Cancers (Basel)*. 2024 Sep 27;16(19):3307. doi: 10.3390/cancers16193307. PMID: 39409927; PMCID: PMC11475878.

38: Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, Onida F, Castagna L, Bramanti S, Carella AM, Sorasio R, Martino M, Alati C, Olivieri A, Beltrami G, Curti A, Vetro C, Leotta S, Mancini V, Terruzzi E, Bernardi M, Galieni P, Musto P, Cerretti R, Giaccone L, Skert C, Radici V, Vezzoli M, Calza S, Leoni A, Garuffo L, Bonvicini C, Pellizzeri S, Malagola M, Ciceri F. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. *Lancet Haematol*. 2024 Nov;11(11):e830-e838. doi: 10.1016/S2352-3026(24)00241-2. Epub 2024 Sep 20. Erratum in: *Lancet Haematol*. 2024 Dec;11(12):e886. doi: 10.1016/S2352-3026(24)00340-5. PMID: 39312920.

39: Nagler A, Labopin M, Swoboda R, Blaise D, Angelucci E, Vydra J, Corral LL, Bramanti S, Chiusolo P, Kwon M, Koc Y, Itälä-Remes M, Martino M, Kulagin A, Busca A, Ciceri F, Mohty M. Young (<35 years) haploidentical versus old (≥35 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2024 Nov;59(11):1552-1562. doi: 10.1038/s41409-024-02400-5. Epub 2024 Aug 18. PMID: 39155338.

40: Alati C, Pitea M, Mico MC, Marafioti V, Greve B, Pratico G, Loteta B, Cogliandro F, Porto G, Policastro G, Utano G, Sgarlata A, Imbalzano L, Delfino IM, Montechiarelo E, Germano J, Filippelli G, Martino M. Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024? *Expert Rev Hematol*. 2024 Aug;17(8):515-525. doi: 10.1080/17474086.2024.2382300. Epub 2024 Jul 21. PMID: 39017205.

41: Bug G, Labopin M, Kulagin A, Blaise D, Raiola AM, Vydra J, Sica S, Kwon M, López-Corral L, Bramanti S, von dem Borne P, Itälä-Remes M, Martino M, Koc Y, Brissot E, Giebel S, Nagler A, Ciceri F, Mohty M. Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT). *Bone Marrow Transplant*. 2024 Oct;59(10):1394-1401. doi: 10.1038/s41409-024-02331-1. Epub 2024 Jul 3. PMID: 38961258; PMCID: PMC11452337.

42: Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Carrabba MG, Cutini I, Martino M, Doderio A, Bonifazi F, Santoro A, Sorà F, Botto B, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Ladetto M, Cavallo F, Massaia M, Arcaini L, Pennisi M, Zinzani PL, Miceli R, Corradini P. A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas. *Blood Cancer Discov*. 2024 Sep 3;5(5):318-330. doi: 10.1158/2643-3230.BCD-24-0052. PMID: 38953781; PMCID: PMC11369587.

43: Robotto A, Olivero C, Pozzi E, Strumia C, Crasà C, Fedele C, Derosa M, Di Martino M, Latino S, Scorza G, Civra A, Lembo D, Quaglini P, Brizio E, Polato D. Efficient wastewater sample filtration improves the detection of SARS-CoV-2 variants: An extensive analysis based on sequencing parameters. *PLoS One*. 2024 May 24;19(5):e0304158. doi: 10.1371/journal.pone.0304158. PMID: 38787865;

PMCID:
PMC11125551.

44: Martino M, Gamberi B, Antonioli E, Aquino S, Della Pepa R, Malerba L, Mangiacavalli S, Pezzatti S, Bringhen S, Zamagni E. Anti-BCMA CAR-T cell-based therapies and bispecific antibodies in the immunotherapy era: are we ready for this? *Expert Rev Hematol.* 2024 Jul;17(7):375-390. doi: 10.1080/17474086.2024.2357274. Epub 2024 May 21. PMID: 38770902.

45: Martino M, Porto G, Policastro G, Alati C, Loteta B, Micó MC, Argiró C, Altomonte M, Moscato T, Labate D, Dattola V, Rao CM, Cogliandro F, Canale FA, Naso V, Filippelli G, Iaria A, Pitea M. Effectiveness of CAR-T treatment toward the potential risk of second malignancies. *Front Immunol.* 2024 May 2;15:1384002. doi: 10.3389/fimmu.2024.1384002. PMID: 38756776; PMCID: PMC11096564.

46: Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Doderò A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. *Leukemia.* 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. PMID: 38459167; PMCID: PMC11073993.

47: Salas MQ, Eikema DJ, Koster L, Maertens J, Passweg J, Finke J, Broers AEC, Koc Y, Kröger N, Ozkurt ZN, Pascual-Cascon MJ, Platzbecker U, Van Gorkom G, Schroeder T, López-Lorenzo JL, Martino M, Chiusolo P, Kaufmann M, Onida F, Gurnari C, Scheid C, Drozd-Sokolowska J, Raj K, Robin M, McLornan DP. Impact of post-transplant cyclophosphamide (PTCy)-based prophylaxis in matched sibling donor allogeneic haematopoietic cell transplantation for patients with myelodysplastic syndrome: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. *Bone Marrow Transplant.* 2024 Apr;59(4):479-488. doi: 10.1038/s41409-023-02159-1. Epub 2024 Jan 22. PMID: 38253869.

48: Martino M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, Germanò J, Alati C, Santoro L, Imbalzano L, Pitea M. Integrating CAR-T cell therapy into the management of DLBCL: what we are learning. *Expert Opin Biol Ther.* 2023 Jul-Dec;23(12):1277-1285. doi: 10.1080/14712598.2023.2292634. Epub 2023 Dec 28. PMID: 38078446.

49: Pitea M, Canale FA, Porto G, Verduci C, Utano G, Policastro G, Alati C, Santoro L, Imbalzano L, Martino M. The Role of MicroRNA in Graft-Versus-Host-Disease: A Review. *Genes (Basel).* 2023 Sep 13;14(9):1796. doi: 10.3390/genes14091796. PMID: 37761936; PMCID: PMC10530280.

50: Canale FA, Pitea M, Alati C, Porto G, Pratico G, Utano G, Germanò J, Imbalzano L, Ferreri A, Verduci C, Santoro L, Policastro G, Loteta B, Pugliese M, Martino M. Case Report: CAR-T cells and subsequent maintenance with ponatinib in an adult Philadelphia acute lymphoblastic leukemia patient with hematological and extramedullary relapse after allogeneic stem cell transplantation. *Eur J Haematol.* 2024 Jan;112(1):137-140. doi: 10.1111/ejh.14087. Epub 2023 Aug 21. PMID: 37605437.

51: Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FA,

Loteta B, Moscato T, Alati C, Ieracitano MC, Cuzzocrea A, Altomonte M, Florenzano MT, Morabito A, Irrera G, Naso V, Pugliese M, Console G, Ferreri A, Imbalzano L, Tripepi G, Pitino A. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. *Ann Hematol.* 2023 Aug;102(8):2297-2298. doi: 10.1007/s00277-023-05323-1. Erratum for: *Ann Hematol.* 2023 Jul;102(7):1915-1925. doi: 10.1007/s00277-023-05228-z. PMID: 37347271; PMCID: PMC10345001.

52: Canale FA, Martino M, Porto G, Verduci C, Console G, Irrera G, Loteta B, Naso V, Pugliese M, Moscato T, Ferreri A, Nappi D, Nicolini F, Mazza M, Martinelli G, Cerchione C. The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic. *Support Care Cancer.* 2023 May 25;31(6):350. doi: 10.1007/s00520-023-07811-6. PMID: 37227523; PMCID: PMC10209549.

53: Martino M, Gori M, Porto G, Pellicano M, Santoro L, Verduci C, Canale FA, Loteta B, Moscato T, Alati C, Ieracitano MC, Cuzzocrea A, Altomonte M, Florenzano MT, Morabito A, Irrera G, Naso V, Pugliese M, Console G, Ferreri A, Imbalzano L, Tripepi G, Pitino A. Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation. *Ann Hematol.* 2023 Jul;102(7):1915-1925. doi: 10.1007/s00277-023-05228-z. Epub 2023 Apr 20. Erratum in: *Ann Hematol.* 2023 Aug;102(8):2297-2298. doi: 10.1007/s00277-023-05323-1. PMID: 37079070; PMCID: PMC10281896.

54: Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. *Nat Med.* 2023 Apr;29(4):869-879. doi: 10.1038/s41591-023-02273-z. Epub 2023 Apr 17. PMID: 37069359; PMCID: PMC10115633.

55: Malagola M, Polverelli N, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, De Gobbi M, Natale A, Terruzzi E, Olivieri A, Chiusolo P, Carella AM, Casini M, Maffini E, Nozzoli C, Mazza P, Bassi S, Onida F, Vacca A, Falcioni S, Luppi M, Iori AP, Pavone V, Skert C, Carluccio P, Borghero C, Proia A, Selleri C, Rubini V, Sacchi N, Oldani E, Bonifazi F, Cicero F, Russo D. Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld Study. *Transplant Direct.* 2023 Feb 22;9(3):e1451. doi: 10.1097/TXD.0000000000001451. PMID: 36845852; PMCID: PMC9949804.

56: Hermans SJF, Versluis J, Labopin M, Giebel S, van Norden Y, Moiseev I, Blaise D, Díez Martín JL, Meijer E, Rovira M, Choi G, Raiola AM, Koc Y, Reményi P, Vydra J, Kröger N, Sica S, Martino M, van Gorkom G, Chevallier P, Busca A, Herrera Arroyo C, Brissot E, Peric Z, Nagler A, Shouval R, Cicero F, Cornelissen JJ, Mohty M. Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. *Hemasphere.* 2023 Feb 21;7(3):e846. doi: 10.1097/HS9.0000000000000846. PMID: 36844179; PMCID: PMC9946411.

- 57: Greco R, Hoogenboom JD, Bonneville EF, Anagnostopoulos A, Cuoghi A, Dalle JH, Weissinger EM, Lang P, Galaverna F, Martino M, Maschan A, Mauz-Körholz C, Noviello M, Passweg J, Peccatori J, Rovira M, Solano C, Veelken H, Velardi A, Wagner-Drouet EM, Zhang X, Ciceri F, Bonini C, Vago L, Ruggeri A, Chabannon C. Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party. *Bone Marrow Transplant.* 2023 May;58(5):603-606. doi: 10.1038/s41409-023-01939-z. Epub 2023 Feb 22. PMID: 36813866; PMCID: PMC9944777.
- 58: Martino M, Canale FA, Naso V, Porto G, Gerace D, Allegra A. Do CAR-T and Allogeneic Stem Cell Transplant Both Have a Place in Lymphoid Neoplasms? *Int J Mol Sci.* 2023 Jan 5;24(2):1045. doi: 10.3390/ijms24021045. PMID: 36674573; PMCID: PMC9861434.
- 59: Martino M, Naso V, Loteta B, Canale FA, Pugliese M, Alati C, Musuraca G, Nappi D, Gaimari A, Nicolini F, Mazza M, Bravaccini S, Derudas D, Martinelli G, Cerchione C. Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon. *Int J Mol Sci.* 2022 Nov 1;23(21):13332. doi: 10.3390/ijms232113332. PMID: 36362130; PMCID: PMC9657035.
- 60: Mariotti J, Raiola AM, Evangelista A, Harbi S, Patriarca F, Carella MA, Martino M, Risitano A, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Chabannon C, Furst S, Santoro A, Bacigalupo A, Bruno B, Blaise D, Mavilio D, Bramanti S, Devillier R, Angelucci E, Castagna L. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide. *Bone Marrow Transplant.* 2022 Dec;57(12):1758-1764. doi: 10.1038/s41409-022-01565-1. Epub 2022 Sep 3. PMID: 36057732.
- 61: Passeri C, Iuliani O, Di Ianni M, Sorrentino C, Giancola R, Abbruzzese L, Dallavalle FM, Gattillo S, Mariano MT, Martino M, Ostuni A, Savignano C, Santoleri L, Tison T, Vacca M, Accorsi P. Comparison between peripheral blood progenitor cell collection on the 4th or 5th day of granulocyte colony-stimulating factor treatment in allogeneic stem cell donors: implications for hematopoietic progenitor cell apheresis guidelines. *Blood Transfus.* 2023 Jan;21(1):37-41. doi: 10.2450/2022.0026-22. Epub 2022 Aug 9. PMID: 35969140; PMCID: PMC9918379.
- 62: Devillier R, Galimard JE, Labopin M, Blaise D, Raiola AM, Pavlu J, Castagna L, Socié G, Chalandon Y, Martino M, Stölzel F, Bug G, Bruno B, Vrhovac R, Charbonnier A, Olivieri A, Bay JO, Arroyo H, Yakoub-Agha I, Avenoso D, Neubauer A, Nguyen S, Forcade E, Brissot E, Savani B, Nagler A, Mohty M. Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. *Bone Marrow Transplant.* 2022 Sep;57(9):1421-1427. doi: 10.1038/s41409-022-01674-x. Epub 2022 Jun 25. PMID: 35752739.
- 63: Bruzzese A, Derudas D, Galli M, Martino EA, Rocco S, Conticello C, Califano C, Giuliani N, Mangiacavalli S, Farina G, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Pietrantuono G, Palumbo G, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Mendicino F, Iaccino E, Mimmi S, Botta C, Vincelli D, Sgherza N,

- Bonalumi A, Cupelli L, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Tripepi G, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Musto P, Boccadoro M, Cavo M, Neri A, Morabito F, Gentile M. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. *Hematol Oncol*. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1. PMID: 35608183.
- 64: Delia M, Carluccio P, Gagliardi VP, Mestice A, Chiusolo P, Arpinati M, Milone GA, Martino M, Mazza P, Ingrosso C, Vacca A, Saporiti G, Zallio F, Attolico I, Pastore D, Specchia G, Albano F, Musto P. Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2022 Jun;57(6):1042-1044. doi: 10.1038/s41409-022-01676-9. Epub 2022 Apr 19. PMID: 35440806.
- 65: Bonifazi F, Pavoni C, Peccatori J, Giglio F, Arpinati M, Busca A, Bernasconi P, Grassi A, Iori AP, Patriarca F, Brunello L, Di Grazia C, Carella AM, Cilloni D, Picardi A, Proia A, Santarone S, Sorasio R, Carluccio P, Chiusolo P, Cupri A, Luppi M, Nozzoli C, Baronciani D, Casini M, Grillo G, Musso M, Onida F, Palazzo G, Parma M, Tringali S, Vacca A, Vallisa D, Sacchi N, Oldani E, Masciulli A, Gheorghiu A, Girmenia C, Martino M, Bruno B, Rambaldi A, Ciceri F; GITMO. Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01. *Bone Marrow Transplant*. 2022 Jun;57(6):949-958. doi: 10.1038/s41409-022-01626-5. Epub 2022 Apr 12. PMID: 35413985; PMCID: PMC9200637.
- 66: Battipaglia G, Galimard JE, Labopin M, Raiola AM, Blaise D, Ruggeri A, Koc Y, Gülbas Z, Vitek A, Sica S, Diez-Martin JL, Castagna L, Bruno B, Rovira M, Moiseev I, Martino M, Grillo G, Araujo MC, Bulabois CE, Nguyen S, Socié G, Arat M, Pavlu J, Tischer J, Martin H, Corral LL, Choi G, Forcade E, McDonald A, Pane F, Bazarbachi A, Ciceri F, Nagler A, Mohty M. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. *Bone Marrow Transplant*. 2022 Apr;57(4):562-571. doi: 10.1038/s41409-022-01577-x. Epub 2022 Jan 25. PMID: 35079140.
- 67: Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, Gülbas Z, Diez-Martin JL, Bruno B, Castagna L, Martino M, Rovira M, Mohty M, Nagler A. The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. *Bone Marrow Transplant*. 2022 Mar;57(3):384-390. doi: 10.1038/s41409-021-01493-6. Epub 2022 Jan 13. PMID: 35022535.
- 68: Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, Giaccone L, Grillo G, Bramanti S, Bernasconi P, De Gobbi M, Natale A, Terruzzi E, Olivieri A, Chiusolo P, Carella AM, Casini M, Nozzoli C, Mazza P, Bassi S, Onida F, Vacca A, Falcioni S, Luppi M, Iori AP, Pavone V, Skert C, Carluccio P, Borghero C, Proia A, Selleri C, Sacchi N, Mammoliti S, Oldani E, Ciceri F, Russo D, Bonifazi F. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥ 60 Years from 2000 to 2017: Improvements and Criticisms. *Transplant Cell Ther*. 2022 Feb;28(2):96.e1-96.e11. doi: 10.1016/j.jtct.2021.11.006. Epub 2021 Nov 21. PMID: 34818581.

- 69: Martino M, Pitino A, Gori M, Viens P, Siena S, Tripepi G, Canale FA, Ballestrero A, Zamagni C, Musso M, Zambelli A, Dreger P, Badoglio M, Secondino S, Console G, Chabannon C, Pedrazzoli P; EBMT Cellular Therapy and Immunobiology Working Party (CTIWP). Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. *Bone Marrow Transplant*. 2022 Feb;57(2):276-278. doi: 10.1038/s41409-021-01503-7. Epub 2021 Oct 23. PMID: 34689176.
- 70: Martino M, Pitino A, Gori M, Bruno B, Crescimanno A, Federico V, Picardi A, Tringali S, Ingrosso C, Carluccio P, Pastore D, Musuraca G, Paviglianiti A, Vacca A, Serio B, Storti G, Mordini N, Leotta S, Cimminiello M, Prezioso L, Loteta B, Ferreri A, Colasante F, Merla E, Giaccone L, Busca A, Musso M, Scalone R, Di Renzo N, Marotta S, Mazza P, Musto P, Attolico I, Selleri C, Canale FA, Pugliese M, Tripepi G, Porto G, Martinelli G, Carella AM Jr, Cerchione C. Letemovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. *Front Oncol*. 2021 Sep 6;11:740079. doi: 10.3389/fonc.2021.740079. PMID: 34616684; PMCID: PMC8489185.
- 71: Martino M, Macheda S, Aguglia U, Arcudi L, Pucci G, Martino B, Altomonte M, Rossetti AM, Cusumano G, Russo L, Imbalzano L, Stelitano C, Alati C, Germano' J, Labate D, Amalfi V, Florenzano MT, Morabito A, Borzumati V, Dattola V, Gattuso C, Moschella A, Quattrone D, Curmaci F, Franzutti C, Scappatura G, Rao CM, Loddo V, Pontari A, Pellicano' M, Surace R, Sanguedolce C, Naso V, Ferreri A, Irrera G, Console G, Moscato T, Loteta B, Canale FA, Trimarchi A, Monteleone R, Al Sayyad S, Cirrone F, Bruno B. Identifying and managing CAR T-cell-mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team. *Expert Opin Biol Ther*. 2022 Mar;22(3):407-421. doi: 10.1080/14712598.2021.1974394. Epub 2021 Sep 15. PMID: 34463175.
- 72: Delia M, Carluccio P, Mestice A, Chiusolo P, Metafuni E, Bellesi S, Arpinati M, Milone GA, Martino M, Mazza P, Ingrosso C, Vacca A, Saporiti G, Zallio F, Attolico I, Pastore D, Specchia G, Albano F, Musto P. The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation. *Transplant Cell Ther*. 2021 Nov;27(11):918.e1-918.e9. doi: 10.1016/j.jtct.2021.08.008. Epub 2021 Aug 14. PMID: 34403789.
- 73: Faraci M, Lorenzi I, Martino M, Mammoliti S, Iurilli V, Serra N, Giardino S, Cannici C, Ciceri F, Botti S. The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo. *J Clin Pharm Ther*. 2021 Dec;46(6):1665-1679. doi: 10.1111/jcpt.13498. Epub 2021 Aug 16. PMID: 34397108.
- 74: Loteta B, Paviglianiti A, Naso V, Ferreri A, Moscato T, Console G, Canale FA, Irrera G, Pugliese M, Di Costanzo A, Provenzano PF, Loddo V, Porto G, Cusumano G, Russo L, Meliambro N, Romeo V, Porcino D, Gallo S, Gangemi T, Rossetti AM, Martino M. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience. *Support Care Cancer*. 2022 Jan;30(1):585-591. doi: 10.1007/s00520-021-06472-7. Epub 2021 Aug 4. PMID: 34347181; PMCID: PMC8331991.

- 75: Morabito F, Tripepi G, Martino EA, Vigna E, Mendicino F, Morabito L, Todoerti K, Al-Janazreh H, D'Arrigo G, Canale FA, Cutrona G, Neri A, Martino M, Gentile M. Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma. *Drug Des Devel Ther.* 2021 Jul 8;15:2969-2978. doi: 10.2147/DDDT.S295215. PMID: 34262262; PMCID: PMC8275138.
- 76: Martino M, Canale FA, Alati C, Vincelli ID, Moscato T, Porto G, Loteta B, Naso V, Mazza M, Nicolini F, Ghelli Luserna di Rorà A, Simonetti G, Ronconi S, Ceccolini M, Musuraca G, Martinelli G, Cerchione C. CART-Cell Therapy: Recent Advances and New Evidence in Multiple Myeloma. *Cancers (Basel).* 2021 May 27;13(11):2639. doi: 10.3390/cancers13112639. PMID: 34072068; PMCID: PMC8197914.
- 77: Picardi A, Sacchi N, Miotti V, Lorentino F, Oldani E, Rambaldi A, Sessa M, Bruno B, Cerno M, Vago L, Bernasconi P, Arcese W, Benedetti F, Pioltelli P, Russo D, Farina L, Fagioli F, Guidi S, Saporiti G, Zallio F, Chiusolo P, Borghero C, Papalinetti G, La Rocca U, Milone G, Lamparelli T, Carella AM, Luppi M, Olivieri A, Martino M, Carluccio P, Celeghini I, Andreani M, Gallina AM, Patriarca F, Pollichieni S, Mammoliti S, Micciché S, Mangione I, Ciceri F, Bonifazi F. Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. *Transplant Cell Ther.* 2021 May;27(5):406.e1-406.e11. doi: 10.1016/j.jtct.2020.11.021. Epub 2021 Feb 16. PMID: 33965179.
- 78: Giammarco S, Sica S, Chiusolo P, Laurenti L, Sorá F, Martino M, Metafuni E, Busca A, Risitano A, Vallejo C, Bacigalupo A. Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study. *Int J Hematol.* 2021 Aug;114(2):228-234. doi: 10.1007/s12185-021-03153-3. Epub 2021 Apr 22. PMID: 33886103.
- 79: Russo D, Polverelli N, Malagola M, Farina M, Leoni A, Bernardi S, Mammoliti S, Sacchi N, Martino M, Ciceri F; GITMO Centers. Changes in Stem Cell Transplant activity and procedures during SARS-CoV2 pandemic in Italy: an Italian Bone Marrow Transplant Group (GITMO) nationwide analysis (TransCOVID-19 Survey). *Bone Marrow Transplant.* 2021 Sep;56(9):2272-2275. doi: 10.1038/s41409-021-01287-w. Epub 2021 Apr 19. PMID: 33875810; PMCID: PMC8054130.
- 80: Zannetti BA, Saraceni F, Cellini C, Fabbri E, Monaco F, Guarini A, Laszlo D, Martino M, Olivieri A, Imola M, Tosi P, Chiarucci M, Zuffa E, Lanza F. Low-Dose Cyclophosphamide versus Intermediate-High-Dose Cyclophosphamide versus Granulocyte Colony-Stimulating Factor Alone for Stem Cell Mobilization in Multiple Myeloma in the Era of Novel Agents: A Multicenter Retrospective Study. *Transplant Cell Ther.* 2021 Mar;27(3):244.e1-244.e8. doi: 10.1016/j.jtct.2020.12.009. Epub 2021 Jan 28. PMID: 33781522.
- 81: Leotta S, Markovic U, Piroso MC, Stella S, Tringali S, Martino M, Specchia G, Carluccio P, Risitano AM, Grimaldi F, Vigna E, Palmieri F, Palmieri R, Annunziata M, Pisapia G, Palazzo G, Milone GA, Pelle AC, Scalise L, Di Giorgio MA, Bulla A, Leotta V, Di Raimondo F, Milone G. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study. *Ann Hematol.* 2021 Jul;100(7):1743-1753. doi: 10.1007/s00277-021-04504-0. Epub 2021 Mar 28. PMID: 33774681.

- 82: Ruggeri A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, Chiusolo P, Diez-Martin JL, Gülbas Z, Castagna L, Bruno B, Arat M, Martino M, Nagler A, Mohty M. Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. *Bone Marrow Transplant*. 2021 Aug;56(8):1842-1849. doi: 10.1038/s41409-021-01248-3. Epub 2021 Mar 5. PMID: 33674790.
- 83: Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. *Int J Mol Sci*. 2021 Feb 21;22(4):2150. doi: 10.3390/ijms22042150. PMID: 33670075; PMCID: PMC7926700.
- 84: Caracciolo D, Riillo C, Ballerini A, Gaipa G, Lhermitte L, Rossi M, Botta C, Duroyon E, Grillone K, Gallo Cantafio ME, Buracchi C, Alampi G, Gulino A, Belmonte B, Conforti F, Golino G, Juli G, Altomare E, Polerà N, Scionti F, Arbitrio M, Iannone M, Martino M, Correale P, Talarico G, Ghelli Luserna di Rorà A, Ferrari A, Concolino D, Sestito S, Pensabene L, Giordano A, Hildinger M, Di Martino MT, Martinelli G, Tripodo C, Asnafi V, Biondi A, Tagliaferri P, Tassone P. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia. *J Immunother Cancer*. 2021 Feb;9(2):e002026. doi: 10.1136/jitc-2020-002026. PMID: 33597219; PMCID: PMC7893666.
- 85: Martino M, Paviglianiti A. An update on B-cell maturation antigen-targeted therapies in Multiple Myeloma. *Expert Opin Biol Ther*. 2021 Aug;21(8):1025-1034. doi: 10.1080/14712598.2021.1872540. Epub 2021 Jan 13. PMID: 33412948.
- 86: Sanz J, Labopin M, Sanz MA, Aljurf M, Sousa AB, Craddock C, Zuckerman T, Labussière-Wallet H, Campos A, Grillo G, Ozkurt ZN, Cornelissen JJ, Reményi P, Martino M, Porrás RP, Nagler A, Gorin NC, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission. *Bone Marrow Transplant*. 2021 Jun;56(6):1272-1280. doi: 10.1038/s41409-020-01162-0. Epub 2020 Dec 15. PMID: 33323947.
- 87: Martino M, Pitino A, Tripepi G, Paviglianiti A, Russo L, Cusumano G, Rossetti A, Provenzano PF, Porto G, Meliambro N, Gallo S, Porcino D, Romeo V, Gangemi T, D'Arrigo G, Imbalzano L, Console G, Gori M. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation. *Clin Lymphoma Myeloma Leuk*. 2021 Apr;21(4):e402-e409. doi: 10.1016/j.clml.2020.11.011. Epub 2020 Nov 20. PMID: 33288484.
- 88: Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C. Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art. *Front Oncol*. 2020 Nov 11;10:592487. doi: 10.3389/fonc.2020.592487. PMID: 33262948; PMCID: PMC7686536.
- 89: Milone G, Conticello C, Leotta S, Michieli MG, Martino M, Marco ALD, Spadaro A, Cupri A, Condorelli A, Milone GA, Markovic U, Sciortino R, Schininà G, Moschetti G, Villari L, Saccardi R; for GITMO. Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable

- cost. *Leuk Res Rep.* 2020 Oct 30;14:100227. doi: 10.1016/j.lrr.2020.100227. PMID: 33204611; PMCID: PMC7649636.
- 90: Gentile M, Morabito F, Martino M, Vigna E, Martino EA, Mendicino F, Martinelli G, Cerchione C. Chemotherapy-based regimens in multiple myeloma in 2020. *Panminerva Med.* 2021 Mar;63(1):7-12. doi: 10.23736/S0031-0808.20.04145-2. Epub 2020 Sep 21. PMID: 32955186.
- 91: Martino M, Paviglianiti A, Gentile M, Martinelli G, Cerchione C. Allogenic stem cell transplantation in multiple myeloma: dead or alive and kicking? *Panminerva Med.* 2020 Dec;62(4):234-243. doi: 10.23736/S0031-0808.20.04142-7. Epub 2020 Sep 21. PMID: 32955185.
- 92: Martino M, Naso V, Porto G, Paviglianiti A, Ferreri A, Loteta B, Moscato T, Console G, Gentile M, Rossi M, Provenzano PF, Gori M, Pitino AL, Morabito A, Tripepi G. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety. *Transfus Apher Sci.* 2020 Dec;59(6):102911. doi: 10.1016/j.transci.2020.102911. Epub 2020 Aug 24. PMID: 32859502.
- 93: Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Harbi S, Furst S, Santoro A, Bacigalupo A, Blaise D, Angelucci E, Mavilio D, Castagna L, Bruno B. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. *Blood Adv.* 2020 Aug 25;4(16):3900-3912. doi: 10.1182/bloodadvances.2020001620. Erratum in: *Blood Adv.* 2020 Nov 24;4(22):5650. doi: 10.1182/bloodadvances.2020003695. PMID: 32813875; PMCID: PMC7448598.
- 94: Botta C, Caruso N, Bossio S, Storino F, Console G, Martino M, Mendicino F, Lucia E, Morelli R, Correale P, Morabito F, Gentile M, Vigna E. Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report. *Front Oncol.* 2020 Jun 18;10:967. doi: 10.3389/fonc.2020.00967. PMID: 32626658; PMCID: PMC7314974.
- 95: Nagler A, Dholaria B, Labopin M, Savani BN, Angelucci E, Koc Y, Arat M, Pioltelli P, Sica S, Gülbas Z, Tischler J, Bernasconi P, Pavlu J, Socié G, Blaise D, Rigacci L, Martino M, Diez-Martin JL, Perić Z, Giebel S, Mohty M. Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia. *Leukemia.* 2020 Oct;34(10):2766-2775. doi: 10.1038/s41375-020-0850-9. Epub 2020 May 11. PMID: 32393841.
- 96: Bacigalupo A, Angelucci E, Raiola AM, Varaldo R, Di Grazia C, Gualandi F, Benedetti E, Risitano A, Musso M, Zallio F, Cicero F, Chiusolo P, Sica S, Rambaldi A, Bonifazi F, Parma M, Martino M, Onida F, Iori AP, Selleri C, Borghero C, Bertaina A, Prezioso L, Algeri M, Locatelli F. Treatment of steroid resistant acute graft versus host disease with an anti-CD26 monoclonal antibody-Begelomab. *Bone Marrow Transplant.* 2020 Aug;55(8):1580-1587. doi: 10.1038/s41409-020-0855-z. Epub 2020 Mar 13. PMID: 32203257.
- 97: Gentile M, Specchia G, Derudas D, Galli M, Botta C, Rocco S, Conticello C,

- Califano C, Giuliani N, Mangiacavalli S, Attingenti E, Lombardo A, Brunori M, Rossi E, Antonioli E, Ria R, Zambello R, Di Renzo N, Mele G, Marcacci G, Musto P, Capalbo S, Cascavilla N, Cerchione C, Belotti A, Criscuolo C, Uccello G, Curci P, Vigna E, Fraticelli V, Vincelli D, Bonalumi A, Siniscalchi A, Stocchi R, Martino M, Ballanti S, Gangemi D, Gagliardi A, Gamberi B, Pompa A, Recchia AG, Tripepi G, Pitino A, Frigeri F, Consoli U, Bringhen S, Zamagni E, Patriarca F, De Stefano V, Di Raimondo F, Palmieri S, Petrucci MT, Offidani M, Boccadoro M, Cavo M, Morabito F. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. *Haematologica*. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513. PMID: 32107338; PMCID: PMC7776255.
- 98: Bazarbachi A, Labopin M, Angelucci E, Gülbas Z, Ozdogu H, Arat M, de Rosa L, Pastano R, Pioltelli P, Montserrat R, Martino M, Ciceri F, Koç Y, Socié G, Blaise D, Herrera C, Chalandon Y, Bernasconi P, Marotta G, Castagna L, McDonald A, Visani G, Carluccio P, Vitek A, Simand C, Afanasyev B, Rösler W, Diez-Martin JL, Nagler A, Brissot E, Giebel S, Mohty M. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for T Cell Acute Lymphoblastic Leukemia: A Report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. *Biol Blood Marrow Transplant*. 2020 May;26(5):936-942. doi: 10.1016/j.bbmt.2020.01.003. Epub 2020 Jan 9. PMID: 31926364.
- 99: Martino M, Gori M, Tripepi G, Recchia AG, Cimminiello M, Provenzano PF, Naso V, Ferreri A, Moscato T, Console G, Loteta B, Gallo GA, Gentile M, Innao V, Rossi M, Morabito A, Vincelli ID, Mannina D, Pitino A. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant. *Ann Hematol*. 2020 Feb;99(2):331-341. doi: 10.1007/s00277-019-03901-w. Epub 2019 Dec 18. PMID: 31853703.
- 100: Morabito F, Recchia AG, Vigna E, Botta C, Skafi M, Abu-Rayyan M, Atrash M, Galimberti S, Morabito L, Al-Janazreh H, Martino M, Cutrona G, Gentile M. An in-depth evaluation of acalabrutinib for the treatment of mantle-cell lymphoma. *Expert Opin Pharmacother*. 2020 Jan;21(1):29-38. doi: 10.1080/14656566.2019.1689959. Epub 2019 Nov 18. PMID: 31738609.
- 101: Martino M, Rossi M, Ferreri A, Loteta B, Morabito A, Moscato T, Console G, Innao V, Naso V, Provenzano PF, Recchia AG, Gentile M. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials. *Expert Rev Hematol*. 2019 Aug;12(8):665-684. doi: 10.1080/17474086.2019.1634541. Epub 2019 Jul 3. PMID: 31251688.
- 102: Shouval R, Labopin M, Gorin NC, Bomze D, Houhou M, Blaise D, Zuckerman T, Baerlocher GM, Capria S, Forcade E, Huynh A, Saccardi R, Martino M, Schaap M, Wu D, Mohty M, Nagler A. Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. *Cancer*. 2019 Oct 15;125(20):3566-3573. doi: 10.1002/cncr.32344. Epub 2019 Jun 21. PMID: 31225904.
- 103: Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, Loteta B, Sanguedolce MC, Console G, Dattola A, Pucci G, Gentile M, Morabito A, Recchia AG, Tripepi G, Pitino A. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34⁺ Cell and Platelet Counts. *Biol Blood Marrow Transplant*. 2019 Aug;25(8):1586-1591. doi: 10.1016/j.bbmt.2019.04.011. Epub 2019 Apr 17. PMID: 31002994.

- 104: Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. *Blood Adv.* 2019 Apr 23;3(8):1197-1210. doi: 10.1182/bloodadvances.2018030387. PMID: 30971397; PMCID: PMC6482353.
- 105: Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, Mountzios G, Peswani N, Porter L, Tanaka TN, Trifirò G, Yang H, Lazo-Langner A. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. *J Clin Oncol.* 2019 May 20;37(15):1336-1351. doi: 10.1200/JCO.18.02142. Epub 2019 Apr 10. PMID: 30969847.
- 106: Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, Di Nardo E, Perseghin P, Olivieri A. Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. *Bone Marrow Transplant.* 2018 Apr;53(4):461-473. doi: 10.1038/s41409-017-0051-y. Epub 2018 Jan 12. PMID: 29330395.
- 107: Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. *Biol Blood Marrow Transplant.* 2018 Mar;24(3):608-613. doi: 10.1016/j.bbmt.2017.09.021. Epub 2017 Oct 13. PMID: 29032271.
- 108: Gentile M, Petrungaro A, Uccello G, Vigna E, Recchia AG, Caruso N, Bossio S, De Stefano L, Palumbo A, Storino F, Martino M, Morabito F. Venetoclax for the treatment of chronic lymphocytic leukemia. *Expert Opin Investig Drugs.* 2017 Nov;26(11):1307-1316. doi: 10.1080/13543784.2017.1386173. Epub 2017 Oct 9. PMID: 28972395.
- 109: Martino M, Console G, Russo L, Meliado' A, Meliambro N, Moscato T, Irrera G, Messina G, Pontari A, Morabito F. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model. *Clin Lymphoma Myeloma Leuk.* 2017 Aug;17(8):506-512. doi: 10.1016/j.clml.2017.05.018. Epub 2017 Jun 6. PMID: 28647402.
- 110: Lanza F, Saraceni F, Pezzi A, Martino M, Bosi A, Cascavilla N, Musto P, Zuffa E, Tani M, Cellini C, Laszlo D, Bonifazi F; GITMO (Italian Society for Transplantation). A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach. *Am J Hematol.* 2017 Sep;92(9):E557-E559. doi: 10.1002/ajh.24817. Epub 2017 Jul 24. PMID: 28612372.
- 111: Milone G, Martino M, Leotta S, Spadaro A, Zammit V, Cupri A, Avola G,

- Camuglia MG, Di Marco A, Scalzulli P, Morelli M, Olivieri A, Tripepi G. Cost-effectiveness of on-demand plerixafor added to chemotherapy and granulocyte-colony stimulating factor for peripheral blood stem cell mobilization in multiple myeloma. *Leuk Lymphoma*. 2018 Jan;59(1):42-48. doi: 10.1080/10428194.2017.1324161. Epub 2017 Jun 2. PMID: 28573902.
- 112: Martino M, Gori M, Pitino A, Gentile M, Dattola A, Pontari A, Vigna E, Moscato T, Recchia AG, Barilla S, Tripepi G, Morabito F. Basal CD34⁺ Cell Count Predicts Peripheral Blood Stem Cell Mobilization in Healthy Donors after Administration of Granulocyte Colony-Stimulating Factor: A Longitudinal, Prospective, Observational, Single-Center, Cohort Study. *Biol Blood Marrow Transplant*. 2017 Jul;23(7):1215-1220. doi: 10.1016/j.bbmt.2017.03.024. Epub 2017 Mar 24. PMID: 28344060.
- 113: Stelitano A, Fedele R, Barilla S, Iaria A, Rao CM, Martino M. Chemotherapy and Cardiotoxicity in Hematologic Malignancies. *Curr Cancer Drug Targets*. 2017;17(4):311-324. doi: 10.2174/1568009617666161121141607. PMID: 27903214.
- 114: Fedele R, Salooja N, Martino M. Recommended screening and preventive evaluation practices of adult candidates for hematopoietic stem cell transplantation. *Expert Opin Biol Ther*. 2016 Nov;16(11):1361-1372. doi: 10.1080/14712598.2016.1229773. Epub 2016 Sep 2. PMID: 27562933.
- 115: Necchi A, Lo Vullo S, Bregni M, Rosti G, Mariani L, Raggi D, Giannatempo P, Secondino S, Schumacher K, Massard C, Kanfer E, Oechsle K, Laszlo D, Michieli M, Ifrah N, Mercier M, Crysandt M, Wuchter P, Nagler A, Wahlin A, Martino M, Badoglio M, Pedrazzoli P, Lanza F; European Society for Blood and Marrow Transplantation (EBMT) Solid Tumors Working Party. Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. *Clin Genitourin Cancer*. 2017 Feb;15(1):163-167. doi: 10.1016/j.clgc.2016.06.013. Epub 2016 Jun 27. PMID: 27444987.
- 116: Gentile M, Martino M, Recchia AG, Vigna E, Morabito L, Morabito F. Sorafenib for the treatment of multiple myeloma. *Expert Opin Investig Drugs*. 2016 Jun;25(6):743-9. doi: 10.1517/13543784.2016.1169272. Epub 2016 Apr 6. PMID: 26998658.
- 117: La Nasa G, Greco M, Littera R, Oppi S, Celeghini I, Caria R, Lai S, Porcella R, Martino M, Romano A, Di Raimondo F, Gallamini A, Carcassi C, Caocci G. The favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma. *J Hematol Oncol*. 2016 Mar 16;9:26. doi: 10.1186/s13045-016-0255-4. PMID: 26983546; PMCID: PMC4793496.
- 118: Fedele R, Martino M, Recchia AG, Irrera G, Gentile M, Morabito F. Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review. *J Immunol Res*. 2015;2015:968212. doi: 10.1155/2015/968212. Epub 2015 Dec 16. PMID: 26788526; PMCID: PMC4695673.
- 119: Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Leno Núñez R, Schouten HC, Bosi A, De Giorgi U, Generali D, Rosti G, Necchi A, Ravelli A, Bengala C, Badoglio M, Pedrazzoli P, Bregni M; European Group for Blood and Marrow Transplantation Solid Tumor Working Party. High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-

Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):475-81. doi: 10.1016/j.bbmt.2015.12.011. Epub 2015 Dec 23. PMID: 26723932.

120: Martino M, Recchia AG, Fedele R, Neri S, Vincelli ID, Moscato T, Gentile M, Morabito F. The role of tandem stem cell transplantation for multiple myeloma patients. *Expert Opin Biol Ther*. 2016;16(4):515-34. doi: 10.1517/14712598.2016.1136285. Epub 2016 Feb 6. PMID: 26698133.

121: Martino M, Festuccia M, Fedele R, Console G, Cimminiello M, Gavarotti P, Bruno B. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. *Expert Opin Biol Ther*. 2016;16(3):347-64. doi: 10.1517/14712598.2015.1130821. Epub 2016 Feb 6. PMID: 26652934.

122: Fedele R, Cuzzola M, Irrera G, Pontari A, D'Ascola DG, Oliva EN, Martino M. Polycythemia following allogeneic hematopoietic progenitor cell transplantation occurring during iron chelation therapy. *Leuk Lymphoma*. 2016;57(4):969-72. doi: 10.3109/10428194.2015.1085533. Epub 2015 Oct 9. PMID: 26308385.

123: Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT). Breast cancer circulating biomarkers: advantages, drawbacks, and new insights. *Tumour Biol*. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. PMID: 26307395.

124: Martino M, Recchia AG, Moscato T, Fedele R, Neri S, Gentile M, Alati C, Vincelli ID, Piro E, Penna G, Musolino C, Ronco F, Molica S, Morabito F. Efficacy of biosimilar granulocyte colony-stimulating factor versus originator granulocyte colony-stimulating factor in peripheral blood stem cell mobilization in de novo multiple myeloma patients. *Cytotherapy*. 2015 Oct;17(10):1485-93. doi: 10.1016/j.jcyt.2015.05.010. Epub 2015 Jul 15. PMID: 26188967.

125: Musso M, Messina G, Marcacci G, Crescimanno A, Console G, Donnarumma D, Scalone R, Pinto A, Martino M. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study. *Biol Blood Marrow Transplant*. 2015 Nov;21(11):1932-8. doi: 10.1016/j.bbmt.2015.06.011. Epub 2015 Jun 19. PMID: 26099830.

126: Pedrazzoli P, Martino M, Delfanti S, Generali D, Rosti G, Bregni M, Lanza F; European Group for Blood and Marrow Transplantation (EBMT), Solid Tumor Working Party. High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for High-Risk Primary Breast Cancer. *J Natl Cancer Inst Monogr*. 2015 May;2015(51):70-5. doi: 10.1093/jncimonographs/lgv010. PMID: 26063892.

127: Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT). Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity. *Expert Rev Anticancer Ther*. 2015 Jun;15(6):689-702. doi: 10.1586/14737140.2015.1042864. Epub 2015 Apr 30. PMID: 25927868.

128: Festuccia M, Martino M, Ferrando F, Messina G, Moscato T, Fedele R,

- Boccadoro M, Giaccone L, Bruno B. Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. *Expert Opin Biol Ther*. 2015 Jun;15(6):857-72. doi: 10.1517/14712598.2015.1036735. Epub 2015 Apr 12. PMID: 25865214.
- 129: Martino M, Moscato T, Barillà S, Dattola A, Pontari A, Fedele R, Furlò G, Marzia Stilo C, Alberto Gallo G, Tripepi G. Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control. *Transfusion*. 2015 Aug;55(8):2032-8. doi: 10.1111/trf.13117. Epub 2015 Apr 9. PMID: 25857853.
- 130: Gentile M, Offidani M, Vigna E, Corvatta L, Recchia AG, Morabito L, Martino M, Morabito F, Gentili S. Smoldering multiple myeloma: to treat or not to treat. *Expert Opin Pharmacother*. 2015 Apr;16(6):785-90. doi: 10.1517/14656566.2015.1007952. Epub 2015 Feb 8. PMID: 25659943.
- 131: Martino M, Bonizzoni E, Moscato T, Recchia AG, Fedele R, Gallo GA, Console G, Messina G, Morabito F. Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age. *Biol Blood Marrow Transplant*. 2015 May;21(5):881-8. doi: 10.1016/j.bbmt.2015.01.021. Epub 2015 Jan 27. PMID: 25636377.
- 132: Martino M, Morabito F. Autologous stem cell transplantation in multiple myeloma is not dead but alive and well. *Expert Opin Biol Ther*. 2015 Feb;15(2):149-54. doi: 10.1517/14712598.2015.988611. Epub 2014 Nov 29. PMID: 25435056.
- 133: Martino M, Lanza F, Demirer T, Moscato T, Secondino S, Pedrazzoli P; European Society for Blood and Marrow Transplantation, Solid Tumors Working Party (EBMT-STWP). Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation. *Expert Opin Biol Ther*. 2015 Feb;15(2):195-211. doi: 10.1517/14712598.2015.971749. Epub 2014 Oct 15. PMID: 25315815.
- 134: Lanza F, Gardellini A, Laszlo D, Martino M. Plerixafor: what we still have to learn. *Expert Opin Biol Ther*. 2015 Feb;15(2):143-7. doi: 10.1517/14712598.2015.971750. Epub 2014 Oct 15. PMID: 25315706.
- 135: Necchi A, Lanza F, Rosti G, Martino M, Farè E, Pedrazzoli P; European Society for Blood and Marrow Transplantation, Solid Tumors Working Party (EBMT-STWP) and the Italian Germ Cell Cancer Group (IGG). High-dose chemotherapy for germ cell tumors: do we have a model? *Expert Opin Biol Ther*. 2015 Jan;15(1):33-44. doi: 10.1517/14712598.2015.963051. Epub 2014 Sep 22. PMID: 25243977.
- 136: Fedele R, Messina G, Martinello T, Gallo GA, Pontari A, Moscato T, Console G, Dattola A, Princi D, Cuzzola M, Alati C, Ronco F, Molica S, Irrera G, Martino M. Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen. *Clin Lymphoma Myeloma Leuk*. 2014 Dec;14(6):493-500. doi: 10.1016/j.clml.2014.04.006. Epub 2014 Jun 11. PMID: 25034142.
- 137: Martino M, Russo L, Martinello T, Gallo GA, Fedele R, Moscato T, Console G, Vincelli DI, Ronco F, Postorino M, Irrera G, Messina G. A home-care, early discharge model after autografting in multiple myeloma: results of a three-arm

prospective, non-randomized study. *Leuk Lymphoma*. 2015 Mar;56(3):801-4. doi: 10.3109/10428194.2014.931952. Epub 2014 Jul 17. PMID: 24913501.

139: Gentile M, Vigna E, Recchia AG, Morabito L, Martino M, Morabito F. Role of new drugs incorporated into consolidation and maintenance therapy in transplant-eligible multiple myeloma patients. *Expert Opin Pharmacother*. 2014 Jul;15(10):1315-20. doi: 10.1517/14656566.2014.919257. Epub 2014 May 12. PMID: 24819321.

140: Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S, Marktel S, Cimminiello M, Messina G, Irrera G, Offidani M, Console G, Castagna L, Milone G, Bruno B, Tripepi G, Lemoli RM, Olivieri A; Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) – Sezione Trapianto Autologo. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. *Biol Blood Marrow Transplant*. 2014 Jul;20(7):1026-32. doi: 10.1016/j.bbmt.2014.03.027. Epub 2014 Mar 31. PMID: 24699116.

141: Martino M, Laszlo D, Lanza F. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. *Expert Opin Biol Ther*. 2014 Jun;14(6):757-72. doi: 10.1517/14712598.2014.895809. Epub 2014 Mar 5. PMID: 24597960.

142: Bertani G, Santoleri L, Martino M, Fedele R, Moscato T, Marengo P, Grillo G, Zucchetti E, Lotesoriere I, Lando G, Cesana C, Cairoli R, Rossini S. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study. *Transfusion*. 2014 Aug;54(8):2028-33. doi: 10.1111/trf.12612. Epub 2014 Mar 3. PMID: 24588265.

143: Martino M, Postorino M, Gallo GA, Messina G, Neri S, Piro E, Gentile M, Moscato T, Monteleone R, Fedele R, Mazzone C, Console G, Penna G, Alati C, Vincelli ID, Irrera G, Musolino C, Ronco F, Molica S, Morabito F. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs. *Clin Lymphoma Myeloma Leuk*. 2014 Apr;14(2):148-54. doi: 10.1016/j.clml.2013.11.009. Epub 2013 Nov 22. PMID: 24417912.

144: Pedrazzoli P, Martinelli G, Gianni AM, Da Prada GA, Ballestrero A, Rosti G, Frassinetti GL, Aieta M, Secondino S, Cinieri S, Fedele R, Bengala C, Bregni M, Grasso D, De Giorgi U, Lanza F, Castagna L, Bruno B, Martino M; of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO) – Sezione Tumori Solidi. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. *Biol Blood Marrow Transplant*. 2014 Apr;20(4):501-6. doi: 10.1016/j.bbmt.2013.12.569. Epub 2013 Dec 27. PMID: 24374214.

145: Milone G, Martino M, Spadaro A, Leotta S, Di Marco A, Scalzulli P, Cupri A, Di Martina V, Schinocca E, Spina E, Tripepi G. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs. *Br J Haematol*. 2014 Jan;164(1):113-23. doi: 10.1111/bjh.12606. Epub 2013 Oct 21. PMID: 24138497.

146: Gentile M, Recchia AG, Mazzone C, Vigna E, Martino M, Morabito L, Lucia E,

- Bossio S, De Stefano L, Granata T, Palumbo A, Morabito F. An old drug with a new future: bendamustine in multiple myeloma. *Expert Opin Pharmacother*. 2013 Nov;14(16):2263-80. doi: 10.1517/14656566.2013.837885. Epub 2013 Sep 21. PMID: 24053161.
- 147: Lanza F, Lemoli RM, Olivieri A, Laszlo D, Martino M, Specchia G, Pavone V, Imola M, Pasini A, Milone G, Scortechini I, Todisco E, Guggiari E, Cascavilla N, Martinelli G, Rambaldi A, Bosi A. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma. *Transfusion*. 2014 Feb;54(2):331-9. doi: 10.1111/trf.12265. Epub 2013 Jun 19. Erratum in: *Transfusion*. 2014 Jun;54(6):1688-91. PMID: 23781769.
- 148: Martino M, Recchia AG, Gentile M, Morabito L, Vigna E, Cuzzola M, Morabito F. Diagnostic approaches for identifying acute graft-versus-host disease: what comes next? *Immunotherapy*. 2013 Jun;5(6):553-6. doi: 10.2217/imt.13.30. PMID: 23725276.
- 149: Martino M, Fedele R, Moscato T, Ronco F. Optimizing outcomes following allogeneic hematopoietic progenitor cell transplantation in AML: the role of hypomethylating agents. *Curr Cancer Drug Targets*. 2013 Jul;13(6):661-9. doi: 10.2174/15680096113139990005. PMID: 23713435.
- 150: Moscato T, Fedele R, Messina G, Irrera G, Console G, Martino M. Hematopoietic progenitor cells transplantation for recurrent or refractory Hodgkin's lymphoma. *Expert Opin Biol Ther*. 2013 Jul;13(7):1013-27. doi: 10.1517/14712598.2013.779250. Epub 2013 Apr 16. PMID: 23586758.
- 151: Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. *Expert Opin Investig Drugs*. 2013 May;22(5):619-34. doi: 10.1517/13543784.2013.788643. Epub 2013 Apr 4. PMID: 23550793.
- 152: Malandrino M, Di Martino M, Giacomino A, Geobaldo F, Berto S, Grosa MM, Abollino O. Temporal trends of elements in Turin (Italy) atmospheric particulate matter from 1976 to 2001. *Chemosphere*. 2013 Mar;90(10):2578-88. doi: 10.1016/j.chemosphere.2012.10.102. Epub 2012 Dec 8. PMID: 23232046.
- 153: Milone G, Tripepi G, Martino M, Ancora F, Bartolozzi B, Spadaro A, Nozzoli C, La Fauci A, Amico I, Leotta S, Poidomani M, Irrera G, Iacopino P, Saccardi R, Guidi S, Bosi A. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor. *Blood Transfus*. 2013 Jan;11(1):94-101. doi: 10.2450/2012.0004-12. Epub 2012 Oct 10. PMID: 23114516; PMCID: PMC3557479.
- 154: Martino M, Bottini A, Rosti G, Generali D, Secondino S, Barni S, Maisano R, Lanza F, Castagna L, Pedrazzoli P. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. *Expert Opin Biol Ther*. 2012 Nov;12(11):1505-15. doi: 10.1517/14712598.2012.721767. Epub 2012 Sep 4. PMID: 22946512.
- 155: Martino M, Montanari M, Bruno B, Console G, Irrera G, Messina G, Offidani M, Scortechini I, Moscato T, Fedele R, Milone G, Castagna L, Olivieri A. Autologous hematopoietic progenitor cell transplantation for multiple myeloma

through an outpatient program. *Expert Opin Biol Ther.* 2012 Nov;12(11):1449-62. doi: 10.1517/14712598.2012.707185. Epub 2012 Jul 13. PMID: 22788745.

156: Martino M, Fedele R, Cornelio G, Moscato T, Imbalzano L, Ressa G, Massara E, Bresolin G. Extracorporeal photopheresis, a therapeutic option for cutaneous T-cell lymphoma and immunological diseases: state of the art. *Expert Opin Biol Ther.* 2012 Aug;12(8):1017-30. doi: 10.1517/14712598.2012.688025. Epub 2012 May 15. PMID: 22587646.

157: Cuzzola M, Fiasché M, Iacopino P, Messina G, Martino M, Console G, Fedele R, Massi D, Recchia AG, Irrera G, Morabito F. A molecular and computational diagnostic approach identifies FOXP3, ICOS, CD52 and CASP1 as the most informative biomarkers in acute graft-versus-host disease. *Haematologica.* 2012 Oct;97(10):1532-8. doi: 10.3324/haematol.2011.059980. Epub 2012 Apr 4. PMID: 22491736; PMCID: PMC3507302.

158: Martino M, Fedele R, Massara E, Recchia AG, Irrera G, Morabito F. Long-term safety of granulocyte colony-stimulating factor in normal donors: is it all clear? *Expert Opin Biol Ther.* 2012 May;12(5):609-21. doi: 10.1517/14712598.2012.674937. Epub 2012 Mar 24. PMID: 22444029.

159: Fedele R, Martino M, Garreffa C, Messina G, Console G, Princi D, Dattola A, Moscato T, Massara E, Spiniello E, Irrera G, Iacopino P. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. *Blood Transfus.* 2012 Apr;10(2):174-80. doi: 10.2450/2012.0034-11. Epub 2012 Jan 24. PMID: 22337266; PMCID: PMC3320776.

160: Martino M, Console G, Russo L, Messina G, D'Arro' BL, Irrera G, Barreca G. Internal iliac artery perforation following bone marrow aspiration in a patient with no previously identified risk factors: a case report and review of the literature. *Acta Haematol.* 2012;127(1):23-5. doi: 10.1159/000331487. Epub 2011 Oct 12. PMID: 21996611.

161: Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A, Martino M, Iacopino P, Milone G, Tedeschi P, Coluzzi S, Nuccorini R, Pascale S, Di Nardo E, Olivieri A. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. *Biol Blood Marrow Transplant.* 2012 Feb;18(2):241-9. doi: 10.1016/j.bbmt.2011.07.014. Epub 2011 Jul 24. PMID: 21791194.

162: Fedele R, Martino M, Dattola A, Cuzzola M, Messina G, Irrera G, Iacopino P. Imatinib mesylate in T-cell large granular lymphocyte leukemia associated with chronic graft-versus-host disease. *Leuk Lymphoma.* 2011 Oct;52(10):2010-1. doi: 10.3109/10428194.2011.584992. Epub 2011 Jun 12. PMID: 21663506.


163: Jannini EA, Isidori AM, Gravina GL, Aversa A, Balercia G, Bocchio M, Boscaro M, Carani C, Corona G, Fabbri A, Foresta C, Forti G, Francavilla S, Granata AR, Maggi M, Mansani R, Palego P, Spera G, Vetri M, Lenzi A; Endotrial Study Group. The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. *J Sex Med.* 2009 Sep;6(9):2547-60. doi: 10.1111/j.1743-6109.2009.01375.x. Epub 2009 Jun 29. PMID: 19570039.

164: Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A,

- Piccione E. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women. *J Obstet Gynaecol Res.* 2009 Feb;35(1):152-9. doi: 10.1111/j.1447-0756.2008.00868.x. PMID: 19215563.
- 165: Messina G, Quartarone E, Console G, Irrera G, Martino M, Pucci G, Le Piane E, Branca D, Cafarelli F, Gangemi A, Iacopino P. Wernicke's encephalopathy after allogeneic stem cell transplantation. *Tumori.* 2007 Mar-Apr;93(2):207-9. doi: 10.1177/030089160709300218. PMID: 17557572.
- 166: Martino M, Luise F, Oriana V, Console G, Moscato T, Mammì C, Messina G, Massara E, Irrera G, Piromalli A, Lombardo VT, Laganà C, Iacopino P. Utility of the clinical practice of administering thrombophilic screening and antithrombotic prophylaxis with low-molecular-weight heparin to healthy donors treated with G-CSF for mobilization of peripheral blood stem cells. *Tumori.* 2007 Mar-Apr;93(2):155-9. doi: 10.1177/030089160709300208. PMID: 17557562.
- 167: Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. *Eur J Haematol.* 2007 Jan;78(1):35-40. doi: 10.1111/j.1600-0609.2006.00774.x. Epub 2006 Oct 17. PMID: 17042773.
- 168: Fruchter O, Zoumakis E, Alesci S, De Martino M, Chrousos G, Hochberg Z. Intracrine modulation of gene expression by intracellular generation of active glucocorticoids. *Steroids.* 2006 Nov;71(11-12):1001-6. doi: 10.1016/j.steroids.2006.08.002. Epub 2006 Sep 22. PMID: 16996097.
- 169: Martino M, Praticò G, Messina G, Irrera G, Massara E, Messina G, Console G, Iacopino P. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients. *Eur J Haematol.* 2006 Nov;77(5):410-5. doi: 10.1111/j.1600-0609.2006.00736.x. Epub 2006 Aug 23. PMID: 16930141.
- 170: Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiattelli M, Iacopino P. High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. *Am J Hematol.* 2006 Dec;81(12):973-8. doi: 10.1002/ajh.20677. PMID: 16888786.
- 171: Martino M, Callea I, Condemi A, Dattola A, Irrera G, Marcuccio D, Messina G, Pontari A, Pucci G, Console G, Iacopino P. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF). *J Clin Apher.* 2006 Oct;21(3):169-75. doi: 10.1002/jca.20082. PMID: 16532489.
- 172: Galimberti S, Benedetti E, Morabito F, Fazzi R, Pacini S, Andreazzoli F, Martino M, Iacopino P, Petrini M. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting. *Transpl Immunol.* 2005 Dec;15(2):173-7. doi: 10.1016/j.trim.2005.06.002. Epub 2005 Jul 25. PMID: 16412962.
- 173: Galimberti S, Benedetti E, Morabito F, Petrini I, Battolla B, Papineschi F, Fazzi R, Ciabatti E, Martino M, Cuzzola M, Console G, Iacopino P, Petrini M. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma

	patients after non-myeloablative transplantation. Leuk Res. 2006 May;30(5):529-35. doi: 10.1016/j.leukres.2005.09.004. Epub 2005 Oct 24. PMID: 16249028. 174: Morabito F, Tomaino A, Cristani M, Cimino F, Martino M, Minciullo PL, Calabrò C, Saija A, Gangemi S. Modification of the content of plasma protein carbonyl groups in donors after granulocyte colony stimulating factor-induced stem cell mobilization. Transfus Apher Sci. 2005 Oct;33(2):141-6. doi: 10.1016/j.transci.2005.05.003. PMID: 16103013. 175: Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res. 2005 Aug;29(8):961-6. doi: 10.1016/j.leukres.2005.01.017. PMID: 15978948. 176: Martino M, Console G, Irrera G, Callea I, Condemi A, Dattola A, Messina G, Pontari A, Pucci G, Furlò G, Bresolin G, Iacopino P, Morabito F. Harvesting peripheral blood progenitor cells from healthy donors: retrospective comparison of filgrastim and lenograstim. J Clin Apher. 2005 Oct;20(3):129-36. doi: 10.1002/jca.20049. PMID: 15892086. 177: Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Pucci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Support Care Cancer. 2005 Mar;13(3):182-7. doi: 10.1007/s00520-004-0686-2. Epub 2004 Oct 6. PMID: 15480819. 178: Martino M, Morabito F, Console G, Irrera G, Pucci G, Penna G, Dattola A, Callea I, Pontari A, Condemi A, Messina G, Nardi M, Cicero G, Molica S, Palazzo S, Iacopino P. High-dose chemotherapy with mitoxantrone + melphalan and autologous stem cell rescue in metastatic breast cancer patients: a study of feasibility and tolerability. Tumori. 2003 Sep-Oct;89(5):492-6. doi: 10.1177/030089160308900506. PMID: 14870770. 179: Martino M, Morabito F, Console G, Irrera G, Messina G, Pucci G, Nardi M, Nobile F, Molica S, Cicero G, Palazzo S, Peta A, Musolino C, Iacopino P. Differences in transplant-related complications between hematologic malignancies and solid tumors receiving high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Tumori. 2003 Jul-Aug;89(4):385-90. doi: 10.1177/030089160308900407. PMID: 14606640. 179: Galimberti S, Morabito F, Guerrini F, Palumbo GA, Azzarà A, Martino M, Benedetti E, Di Raimondo F, Petrini M. Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients. Br J Haematol. 2003 Feb;120(3):405-12. doi: 10.1046/j.1365-2141.2003.04106.x. PMID: 12580954. 180: Morabito F, Martino M, Stelitano C, Oliva E, Kropp M, Irrera G, Console G, Fujo M, Messina G, Molica S, Callea V, Iacopino P. Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica. 2002 Nov;87(11):1192-9. PMID: 12414350.
	“Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae” <i>I dati personali inseriti sono trattati ai sensi di quanto previsto dal GDPR 679/2018 e</i>

Reggio Calabria 28-01-2026

A handwritten signature in black ink, appearing to read "Massimo Martino". The signature is fluid and cursive, with the first name "Massimo" and the last name "Martino" clearly distinguishable.